Stocksigma LogoStocksigma Logo

Epigral Reports Strong Q2 FY27 With PAT Surging 26% YoY to ₹64 Crore

Epigral reported a 26% YoY rise in Q2 FY27 PAT to ₹64 Cr, while revenue increased 28% YoY to ₹752 Cr, driven by improved realisations and 6% sales volume

Epigral Reports Strong Q2 FY27 With PAT Surging 26% YoY to ₹64 Crore

Epigral Ltd · Press Release · 02 Nov 2026, 7:29 pm

Epigral Reports Strong Q2 FY27 With PAT Surging 26% YoY to ₹64 Crore Epigral reported a 26% YoY rise in Q2 FY27 PAT to ₹64 Cr, while revenue increased 28% YoY to ₹752 Cr, driven by improved realisations and 6% sales volume growth. Derivatives and Specialty contribution rose to 57% of revenue versus 50% in Q2 FY26. EBITDA grew to ₹136 Cr, with margins at 18% due to elevated raw material costs. For H1 FY27, revenue reached ₹1,461 Cr and PAT hit ₹164 Cr. Expansions in CPVC and ECH are slated for commissioning within a quarter.

Original exchange filing (PDF)

More announcements from Epigral Ltd

All Epigral Ltd announcements